Diagnostic biomarkers for Parkinson's disease at a glance: where are we?

J Neural Transm (Vienna). 2018 Oct;125(10):1417-1432. doi: 10.1007/s00702-018-1910-4. Epub 2018 Aug 25.

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder whose aetiology remains unclear: degeneration involves several neurotransmission systems, resulting in a heterogeneous disease characterized by motor and non-motor symptoms. PD causes progressive disability that responds only to symptomatic therapies. Future advances include neuroprotective strategies for use in at-risk populations before the clinical onset of disease, hence the continuing need to identify reliable biomarkers that can facilitate the clinical diagnosis of PD. In this evaluative review, we summarize information on potential diagnostic biomarkers for use in the clinical and preclinical stages of PD.

Keywords: Biomarkers; Diagnosis; Parkinson’s disease.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Brain / pathology
  • Cognition Disorders / etiology
  • Constipation / etiology
  • Depression / etiology
  • Early Diagnosis
  • Genetic Predisposition to Disease
  • Humans
  • Inflammation
  • Levodopa / pharmacology
  • Levodopa / therapeutic use
  • Metabolomics
  • Microbiota
  • Movement Disorders / etiology
  • Neuroimaging
  • Olfaction Disorders / etiology
  • Parkinson Disease / complications
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / diagnostic imaging
  • Parkinson Disease / pathology
  • REM Sleep Behavior Disorder / etiology
  • Symptom Assessment
  • Vision Disorders / etiology
  • alpha-Synuclein / analysis

Substances

  • Biomarkers
  • alpha-Synuclein
  • Levodopa